Ownership Submission

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:

3235-0104

Estimated average burden hours per response...

0.5

(Print or Type Responses)

1. Name and Address of Reporting Person ^*

Kipke Arthur Karl

2. Date of Event Requiring Statement (Month/Day/Year)
02/12/2014

3. Issuer Name and Ticker or Trading Symbol
AMEDICA Corp [AMDA]

(Last)

(First)

(Middle)

C/O HAMPSHIRE GROUP, LLC,, 500 PLAZA ON THE LAKE, SUITE #103

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

_____ Director	__X__ 10% Owner
_____ Officer (give title below)	_____ Other (specify below)

5. If Amendment, Date Original Filed(Month/Day/Year)

(Street)

AUSTIN, TX 78746

6. Individual or Joint/Group Filing(Check Applicable Line)
_X_ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person

(City)

(State)

(Zip)

Table I - Non-Derivative Securities Beneficially Owned

1.Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Common Stock	53,347	I	By Hampshire Med Tech Partners, LP ⁽¹⁾

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.			SEC 1473 (7-02)
	Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
1. Title of Derivative Security (Instr. 4)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	4. Conversion or Exercise Price of Derivative Security		6. Nature of Indirect Beneficial Ownership (Instr. 5)
Warrant to Purchase Shares of Common Stock	⁽²⁾	⁽²⁾	Common Stock	13,975 ⁽²⁾	$ ⁽²⁾	D
Warrant to Purchase Shares of Common Stock	⁽³⁾	⁽³⁾	Common Stock	96,994 ⁽³⁾	$ ⁽³⁾	I	By Hampshire Med Tech Partners, LP ⁽¹⁾
Warrant to Purchase Shares of Series E Convertible Preferred	⁽⁴⁾	⁽⁴⁾	Common Stock	2,204 ⁽⁴⁾	$ ⁽⁴⁾	D
Series D Convertible Preferred Stock	⁽⁵⁾	⁽⁵⁾	Common Stock	16,919 ⁽⁵⁾	$ ⁽⁵⁾	I	By Hampshire Asset Managements, LLC ⁽⁶⁾
Series D Convertible Preferred Stock	⁽⁵⁾	⁽⁵⁾	Common Stock	115,655 ⁽⁵⁾	$ ⁽⁵⁾	I	By KM Healthcare Holdings ⁽⁷⁾
Series D-1 Convertible Preferred Stock	⁽⁸⁾	⁽⁸⁾	Common Stock	11,821 ⁽⁸⁾	$ ⁽⁸⁾	I	By Hampshire Healthcare Partners LP ⁽⁹⁾
Series E Convertible Preferred Stock	⁽¹⁰⁾	⁽¹⁰⁾	Common Stock	14,087 ⁽¹⁰⁾	$ ⁽¹⁰⁾	I	By Hampshire Healthcare Partners LP ⁽⁹⁾
Series F Convertible Preferred Stock	⁽¹¹⁾	⁽¹¹⁾	Common Stock	1,250,009 ⁽¹¹⁾	$ ⁽¹¹⁾	I	By Hampshire Med Tech Partners, LP ⁽¹⁾

Reporting Owners

Reporting Owner Name / Address	Relationships
Reporting Owner Name / Address	Director	10% Owner	Officer	Other
Kipke Arthur Karl C/O HAMPSHIRE GROUP, LLC, 500 PLAZA ON THE LAKE, SUITE #103 AUSTIN, TX 78746		X

Signatures

/s/ Jonathan Ursprung		02/12/2014
^**Signature of Reporting Person		Date

Explanation of Responses:

*	If the form is filed by more than one reporting person, see Instruction 5(b)(v).
**	Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
(1)	Shares held by Hampshire Med Tech Partners, LP, of which the Reporting Person is the managing member of the general partner, Hampshire Med Tech Partners GP, LLC. The Reporting Person disclaims beneficial ownership except to the extent of any pecuniary interest therein.
(2)	Includes of a warrant to purchase 12,027 shares of Common Stock at an exercise price of $56.70 per share of Common Stock exercisable at any time and expiring on May 9, 2016; and a warrant to purchase 1,948 shares of Common Stock at a strike price of $85.06 per share of Common Stock exercisable at any time and expiring on June 2, 2015.
(3)	Consists of a warrant to purchase 96,994 shares of Common Stock at a strike price of $17.53 per share of Common Stock exercisable at any time and expiring on March 4, 2018.
(4)	Consists of a warrant to purchase 50,000 shares of Series E convertible preferred stock which, upon completion of the Issuer's initial public offering, will be converted to a warrant to purchase 2,204 shares of the Issuer's Common Stock at an exercise price of $56.70 per share, terminating in April 2015. This conversion is reflected in column 3 in the amount of securities underlying the derivative securities.
(5)	Upon the closing of the Issuer's initial public offering of shares of its Common Stock, each share of Series D Convertible Preferred Stock will convert into 1.3014 shares of the Issuer's Common Stock pursuant to the terms of the Certificate of Designation for Series D Convertible Preferred Stock of the Issuer. This conversion is reflected in column 3 in the amount of securities underlying the derivative securities.
(6)	Shares held by Hampshire Asset Managements, LLC, of which the Reporting Person is the presdent. The Reporting Person disclaims beneficial ownership except to the extent of any pecuniary interest therein.
(7)	Shares held by KM Healthcare Holdings LP. The Reporting Person shares voting and dispositive power with the general partner of KM Healthcare Holdings LP. The Reporting Person disclaims beneficial ownership except to the extent of any pecuniary interest therein.
(8)	Upon the closing of the Issuer's initial public offering of shares of its Common Stock, each share of Series D-1 Convertible Preferred Stock will convert into 1.6834 shares of the Issuer's Common Stock pursuant to the terms of the Certificate of Designation for Series D-1 Convertible Preferred Stock of the Issuer. This conversion is reflected in column 3 in the amount of securities underlying the derivative securities.
(9)	Shares held by Hampshire Healthcare Partners LP, of which the Reporting Person is the managing member of the general partner, Hampshire Special Opportunities, LLC. The Reporting Person disclaims beneficial ownership except to the extent of any pecuniary interest therein.
(10)	Upon the closing of the Issuer's initial public offering of shares of its Common Stock, each share of Series E Convertible Preferred Stock will convert into 1.1363 shares of the Issuer's Common Stock pursuant to the terms of the Certificate of Designation for Series E Convertible Preferred Stock of the Issuer. This conversion is reflected in column 3 in the amount of securities underlying the derivative securities.
(11)	Upon the closing of the Issuer's initial public offering of shares of its Common Stock, each share of Series F Convertible Preferred Stock will convert into 6.44370 shares of the Issuer's Common Stock pursuant to the terms of the Certificate of Designation for Series F Convertible Preferred Stock of the Issuer. This conversion is reflected in column 3 in the amount of securities underlying the derivative securities.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, See Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.